Detalles de la búsqueda
1.
Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.
J Clin Psychopharmacol
; 43(2): 113-121, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36700734
2.
No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.
Eur Respir J
; 53(1)2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30442716
3.
A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
Future Oncol
; 11(10): 1479-91, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25963426
4.
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
Breast Cancer Res Treat
; 133(3): 1057-65, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22418700
5.
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 134(3): 1149-59, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22763464
6.
A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Eur J Drug Metab Pharmacokinet
; 47(1): 81-89, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34664183
7.
Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
Eur J Drug Metab Pharmacokinet
; 47(1): 91-103, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716565
8.
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Clin Pharmacokinet
; 58(9): 1131-1147, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31016670
9.
Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study.
Eur J Drug Metab Pharmacokinet
; 43(2): 239-249, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29076028
10.
Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.
Clin Drug Investig
; 38(8): 737-750, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29846887
11.
Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies.
Clin Transl Sci
; 11(6): 616-623, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30136756
12.
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
Clin Pharmacokinet
; 56(3): 235-250, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27470518
13.
Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
Eur J Drug Metab Pharmacokinet
; 42(3): 461-469, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27436099
14.
A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.
Springerplus
; 5: 45, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26835225
15.
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Neuro Oncol
; 17(3): 430-9, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25140039
16.
Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors.
Cancer Chemother Pharmacol
; 73(4): 759-70, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24522402
17.
Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir.
Clin Drug Investig
; 34(3): 173-82, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24399452
18.
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
Cancer Chemother Pharmacol
; 74(2): 267-75, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24906422
19.
Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
Clin Pharmacokinet
; 52(12): 1101-9, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23813493
20.
Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition.
Hypertension
; 56(3): 490-7, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20606112